Skip to main content

Drug Interactions between digoxin and Ventolin

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

digoxin albuterol

Applies to: digoxin and Ventolin (albuterol)

MONITOR: Coadministration with albuterol decreases digoxin's serum concentration. The mechanism of action may involve an albuterol-induced increased distribution of digoxin to skeletal muscle. In a pharmacokinetic study, ten healthy patients were administered digoxin 0.5 mg daily for 10 days and then they were administered a single 3 mg or 4 mg oral dose of albuterol. This study reported a 22% decrease in serum digoxin levels and a 14% decrease in serum potassium after the albuterol dose. In addition, the effects of hypokalemia caused by beta-2 agonists such as albuterol may lead to an increased risk of digitalis induced arrhythmias. The clinical significance for patients who are receiving albuterol inhalation and digoxin is unclear.

MANAGEMENT: Caution is advised if albuterol is used concomitantly with digoxin. Monitoring of serum digoxin and potassium concentrations may be required. Clinical monitoring for digoxin toxicity and/or hypokalemia, particularly in patients at risk of hypokalemia should also be considered. Dosage adjustments for either medication may also be required whenever digoxin and albuterol are used concurrently. Patients should be advised to seek immediate medical attention if they experience signs of arrhythmias, such as sudden dizziness, lightheadedness, fainting, shortness of breath, or irregular heartbeats.

References

  1. Edner M, Jogestrand T, Dahlqvist R (1992) "Effect of salbutamol on digoxin pharmacokinetics." Eur J Clin Pharmacol, 42, p. 197-201
  2. Edner M, Jogestrand T (1990) "Oral salbutamol decreases serum digoxin concentration." Eur J Clin Pharmacol, 38, p. 195-7
  3. (2002) "Product Information. Proventil (albuterol)." Schering Corporation
  4. (2002) "Product Information. Ventolin (albuterol)." Glaxo Wellcome
  5. (2001) "Product Information. Xopenex (levalbuterol)." Sepracor Inc
  6. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  7. Cerner Multum, Inc. "Australian Product Information."
  8. Agencia Española de Medicamentos y Productos Sanitarios Healthcare (2008) Centro de información online de medicamentos de la AEMPS - CIMA. https://cima.aemps.es/cima/publico/home.html
View all 8 references

Switch to consumer interaction data

Drug and food interactions

Moderate

albuterol food

Applies to: Ventolin (albuterol)

MONITOR: Coadministration of two or more sympathomimetic agents may increase the risk of adverse effects such as nervousness, irritability, and increased heart rate. Central nervous system (CNS) stimulants, particularly amphetamines, can potentiate the adrenergic response to vasopressors and other sympathomimetic agents. Additive increases in blood pressure and heart rate may occur due to enhanced peripheral sympathetic activity.

MANAGEMENT: Caution is advised if two or more sympathomimetic agents are coadministered. Pulse and blood pressure should be closely monitored.

References

  1. Rosenblatt JE, Lake CR, van Kammen DP, Ziegler MG, Bunney WE Jr (1979) "Interactions of amphetamine, pimozide, and lithium on plasma norepineophrine and dopamine-beta-hydroxylase in schizophrenic patients." Psychiatry Res, 1, p. 45-52
  2. Cavanaugh JH, Griffith JD, Oates JA (1970) "Effect of amphetamine on the pressor response to tyramine: formation of p-hydroxynorephedrine from amphetamine in man." Clin Pharmacol Ther, 11, p. 656
  3. (2001) "Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc
  4. (2001) "Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals
  5. (2001) "Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals
  6. (2001) "Product Information. Focalin (dexmethylphenidate)." Mikart Inc
  7. (2002) "Product Information. Strattera (atomoxetine)." Lilly, Eli and Company
View all 7 references

Switch to consumer interaction data

Minor

digoxin food

Applies to: digoxin

Administration of digoxin with a high-fiber meal has been shown to decrease its bioavailability by almost 20%. Fiber can sequester up to 45% of the drug when given orally. Patients should be advised to maintain a regular diet without significant fluctuation in fiber intake while digoxin is being titrated.

Grapefruit juice may modestly increase the plasma concentrations of digoxin. The mechanism is increased absorption of digoxin due to mild inhibition of intestinal P-glycoprotein by certain compounds present in grapefruits. In 12 healthy volunteers, administration of grapefruit juice with and 30 minutes before, as well as 3.5, 7.5, and 11.5 hours after a single digoxin dose (0.5 mg) increased the mean area under the plasma concentration-time curve (AUC) of digoxin by just 9% compared to administration with water. Moreover, P-glycoprotein genetic polymorphism does not appear to influence the magnitude of the effects of grapefruit juice on digoxin. Thus, the interaction is unlikely to be of clinical significance.

References

  1. Darcy PF (1995) "Nutrient-drug interactions." Adverse Drug React Toxicol Rev, 14, p. 233-54
  2. Becquemont L, Verstuyft C, Kerb R, et al. (2001) "Effect of grapefruit juice on digoxin pharmacokinetics in humans." Clin Pharmacol Ther, 70, p. 311-6

Switch to consumer interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer